Inhibition of miR-483-3p promotes gefitinib resistance in EGFR-mutant NSCLC, suggesting that miR-483-3p is a promising target to overcome acquired EGFR TKI resistance in EGFR-mutant NSCLC (Yue et al., 2018). Here, EGFR is linked to non-small cell lung carcinoma.